# Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER: UK GMP 18729 Insp GMP 18729/376405-0002[H]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER (1),(2)

## Part 1

Issued following an inspection in accordance with:

Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following:

The Manufacturer: BIORELIANCE CORPORATION

Site address: BIORELIANCE CORPORATION, 14920 BROSCHART ROAD, ROCKVILLE, 20850-3349, UNITED STATES

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Regulation 327 of The Human Medicines Regulations 2012 (SI 2012/1916)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 15/07/2013, it is considered that it complies with

• The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

#### Part 2

#### **Human Medicinal Products**

- 1. MANUFACTURING OPERATIONS
- [ 1.3 ] Biological medicinal products

[ 1.3.1 ] Biological medicinal products

[ 1.3.1.5 ] Biotechnology products

[ 1.3.1.6 ] Human or animal extracted products

[ 1.3.1.8 ] Other biological medicinal products
Cell Bank Production for Use in Manufacturing of Testing

### [ 1.6 ] Quality control testing

[ 1.6.1 ] Microbiological: sterility

[ 1.6.2 ] Microbiological: non-sterility

[ 1.6.4 ] Biological

Any restrictions related to the scope of this certificate:

Building Room Line/equipment QC Testing	Products
BioReliance, Rockville cond	nducts contract Numerous EU medicinal product including Prevenar 13;
biological testing such as m	mycoplasma Prolia; Pumarix; Nulojix; Aldurazyme; Aranesp; Zaltrap;
and adventitous virus agen	nt testing. It Adcetris; Arzerra; Yervoy; XGEVA; Vectibix; Orencia;
also acts as a storage facili	lity for client Eylea; Naglazyme; ReFacto AF; Vimizim; NovoSeven;
cell banks.	Tysabri; Fluenz Tetra; Fluenz and Stelara

25/09/2013 Name and signature of the authorised person of the Competent Authority of United Kingdom

Confidential

Medicines and Healthcare products Regulatory Agency

Tel: Confidential